PamBio

Company Overview

Snapshot

Founded in April 2014 by Abd Al-Roof Higazi and Dr. Nuha Higazi, PamBio operated with 1–10 employees. The company raised a total of $10M across two funding rounds from three investors. In July 2016, PamBio secured its last known funding round.

Business overview

PamBio is a biotechnology company focused on developing drug therapies for acute bleeding conditions, specifically hemorrhagic stroke, including intracranial bleeding and ICH. The company's core technology is an inactive recombinant mutant-tPA protein, designed to be a competitive inhibitor to native-tPA. This therapeutic biomolecule offers both antifibrinolytic and neuroprotective effects by blocking tPA and uPA fibrinolysis enzyme activity and limiting tPA and glutamate-mediated neurotoxicity. PamBio operates within the Health Tech & Life Sciences sector, with a focus on Pharmaceuticals, Drug Discovery & Development, serving global markets.

Strategic signal

In March 2017, PamBio's co-founder highlighted the company's unique position in developing a treatment to stop cerebral hemorrhage. This indicates the company's focus on addressing a critical unmet medical need and signals its potential to disrupt the stroke treatment market with a novel therapeutic approach.

Company Intelligence Q&A

What is PamBio's primary focus in drug development?

PamBio is developing drug therapy for hemorrhagic stroke, including intracranial bleeding and ICH, and other acute bleeding conditions.

When was PamBio founded and by whom?

PamBio was founded in April 2014 by Abd Al-Roof Higazi and Dr. Nuha Higazi.

What is the core mechanism of PamBio's drug therapy?

PamBio's solution uses an inactive recombinant mutant-tPA protein that acts as a competitive inhibitor to native-tPA, providing both antifibrinolytic and neuroprotective effects.

Which investors participated in PamBio's Seed round in January 2015?

In January 2015, PamBio received Seed funding from NGT3 and Office of the Chief Scientist.